|
Enanta Pharmaceuticals, Inc. (Enta) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Enanta Pharmaceuticals, Inc. (ENTA) Bundle
¡Descubra el verdadero valor de Enanta Pharmaceuticals, Inc. (Enta) con nuestra calculadora DCF de grado profesional! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo diferentes cambios afectan la valoración de Enanta Pharmaceuticals, Inc. (Enta), todo en una plantilla integral de Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 122.5 | 97.1 | 86.2 | 79.2 | 67.6 | 58.4 | 50.4 | 43.5 | 37.6 | 32.4 |
| Revenue Growth, % | 0 | -20.74 | -11.24 | -8.07 | -14.61 | -13.67 | -13.67 | -13.67 | -13.67 | -13.67 |
| EBITDA | -38.0 | -104.2 | -119.2 | -123.5 | -104.5 | -50.3 | -43.5 | -37.5 | -32.4 | -28.0 |
| EBITDA, % | -31.02 | -107.39 | -138.36 | -155.9 | -154.52 | -86.2 | -86.2 | -86.2 | -86.2 | -86.2 |
| Depreciation | 3.6 | 3.3 | 3.0 | 2.4 | 2.3 | 1.9 | 1.6 | 1.4 | 1.2 | 1.1 |
| Depreciation, % | 2.98 | 3.43 | 3.45 | 2.99 | 3.45 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 |
| EBIT | -41.6 | -107.6 | -122.2 | -125.8 | -106.8 | -50.7 | -43.8 | -37.8 | -32.6 | -28.2 |
| EBIT, % | -34 | -110.82 | -141.82 | -158.89 | -157.98 | -86.8 | -86.8 | -86.8 | -86.8 | -86.8 |
| Total Cash | 386.6 | 244.0 | 249.2 | 369.9 | 248.2 | 58.4 | 50.4 | 43.5 | 37.6 | 32.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.5 | 60.8 | 49.0 | 39.6 | 6.6 | 23.2 | 20.0 | 17.3 | 14.9 | 12.9 |
| Account Receivables, % | 19.18 | 62.66 | 56.91 | 50.02 | 9.83 | 39.72 | 39.72 | 39.72 | 39.72 | 39.72 |
| Inventories | .0 | -37.3 | .0 | .0 | .0 | -4.5 | -3.9 | -3.3 | -2.9 | -2.5 |
| Inventories, % | 0 | -38.38 | 0 | 0 | 0 | -7.68 | -7.68 | -7.68 | -7.68 | -7.68 |
| Accounts Payable | 5.7 | 9.5 | 6.0 | 4.1 | 8.0 | 4.5 | 3.9 | 3.3 | 2.9 | 2.5 |
| Accounts Payable, % | 4.68 | 9.83 | 6.96 | 5.17 | 11.83 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 |
| Capital Expenditure | -1.4 | -.8 | -2.1 | -9.1 | -17.9 | -5.0 | -4.3 | -3.7 | -3.2 | -2.8 |
| Capital Expenditure, % | -1.18 | -0.77261 | -2.47 | -11.44 | -26.54 | -8.48 | -8.48 | -8.48 | -8.48 | -8.48 |
| Tax Rate, % | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 |
| EBITAT | -43.0 | -79.0 | -121.8 | -128.6 | -105.3 | -47.8 | -41.3 | -35.6 | -30.8 | -26.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -58.6 | -72.7 | -149.9 | -127.7 | -84.0 | -66.4 | -42.0 | -36.2 | -31.3 | -27.0 |
| WACC, % | 10.96 | 9.36 | 10.93 | 10.96 | 10.87 | 10.62 | 10.62 | 10.62 | 10.62 | 10.62 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -158.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -28 | |||||||||
| Terminal Value | -320 | |||||||||
| Present Terminal Value | -193 | |||||||||
| Enterprise Value | -351 | |||||||||
| Net Debt | 18 | |||||||||
| Equity Value | -370 | |||||||||
| Diluted Shares Outstanding, MM | 21 | |||||||||
| Equity Value Per Share | -17.47 |
What You Will Get
- Editable Forecast Inputs: Effortlessly modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Enanta Pharmaceuticals, Inc.'s (ENTA) financial data pre-loaded to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you automatically.
- Customizable and Professional: A sleek Excel model tailored to fit your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Enanta Pharmaceuticals, Inc. (ENTA).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the pharmaceutical sector.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit Enanta's financial outlook.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Enanta Pharmaceuticals, Inc. (ENTA).
- Visual Dashboard and Charts: Present visual summaries of key valuation metrics for straightforward analysis and decision-making.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Enanta Pharmaceuticals' pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Enanta Pharmaceuticals, Inc. (ENTA)?
- Accurate Data: Utilize real Enanta Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Easy-to-navigate design and step-by-step guidance cater to users of all experience levels.
Who Should Use This Product?
- Investors: Assess the fair value of Enanta Pharmaceuticals (ENTA) to inform your investment choices.
- CFOs: Utilize a high-quality DCF model for accurate financial reporting and analysis related to Enanta Pharmaceuticals (ENTA).
- Consultants: Efficiently modify the template for client valuation reports involving Enanta Pharmaceuticals (ENTA).
- Entrepreneurs: Discover financial modeling techniques employed by leading pharmaceutical companies, including Enanta Pharmaceuticals (ENTA).
- Educators: Implement it as a resource for teaching valuation methods in the context of Enanta Pharmaceuticals (ENTA).
What the Template Contains
- Pre-Filled DCF Model: Enanta Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Enanta Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.